Weekly Investment Analysts’ Ratings Changes for Avantor (AVTR)

A number of firms have modified their ratings and price targets on shares of Avantor (NYSE: AVTR) recently:

• 11/4/2025 – Avantor was downgraded by analysts at Raymond James Financial, Inc. from an “outperform” rating to a “market perform” rating.
• 10/30/2025 – Avantor was given a new $12.00 price target on by analysts at UBS Group AG.
• 10/30/2025 – Avantor had its price target lowered by analysts at Evercore ISI from $16.00 to $14.00. They now have an “outperform” rating on the stock.
• 10/30/2025 – Avantor had its “equal weight” rating reaffirmed by analysts at Barclays PLC. They now have a $12.00 price target on the stock, down previously from $15.00.
• 10/30/2025 – Avantor had its “neutral” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $12.00 price target on the stock, down previously from $14.00.
• 10/24/2025 – Avantor had its price target raised by analysts at Robert W. Baird from $15.00 to $17.00. They now have an “outperform” rating on the stock.
• 10/16/2025 – Avantor had its price target raised by analysts at Raymond James Financial, Inc. from $14.00 to $16.00. They now have an “outperform” rating on the stock.
• 10/2/2025 – Avantor had its price target raised by analysts at Barclays PLC from $13.00 to $15.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling

In related news, Director Gregory L. Summe bought 100,000 shares of the company’s stock in a transaction on Thursday, October 30th. The shares were bought at an average price of $11.25 per share, with a total value of $1,125,000.00. Following the transaction, the director owned 300,000 shares in the company, valued at approximately $3,375,000. This trade represents a 50.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.20% of the stock is owned by company insiders.

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.